The impact of discontinuing proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors on clinical outcomes

Back

ESC Professional Premium Access

The impact of discontinuing proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors on clinical outcomes

Session: Lipid-lowering therapies: new findings

Topic: Drug therapy

Speaker: Doctor H. Tsubata (Kyoto, JP)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Hideo Tsubata

Kyoto Prefectural University of Medicine, Kyoto (Japan)

0 follower

8 more presentations in this session

Rationale and design of the SHASTA-3 and SHASTA-4 studies: randomized, double-blind, placebo-controlled, phase 3 studies of plozasiran in patients with severe hypertriglyceridemia

Speaker: Doctor D. Gaudet (Montreal, CA)

Changes in lipid lowering therapy one year after percutaneous coronary intervention: data from the large contemporary ZON-HR registry

Speaker: Ms D. Peeters (Nijmegen, NL)

Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis

Speaker: Doctor D. Mutschlechner (Mistelbach, AT)

Association of lipid target achievement and cardiovascular outcomes following statin initiation: a population-based cohort study

Speaker: Doctor J. Udell (Toronto, CA)

Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events

Speaker: Doctor I. Dykun (Essen, DE)

Access the full session

Lipid-lowering therapies: new findings

Speakers: Doctor H. Tsubata, Doctor D. Gaudet, Ms D. Peeters, Doctor D. Mutschlechner, Doctor J. Udell...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources